A carregar...
The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
Trials on cardiovascular and renal outcomes in patients with type 2 diabetes have consistently demonstrated that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of diabetic kidney disease (DKD) progression. However, their renal protective mechanisms have yet to be completely unders...
Na minha lista:
| Publicado no: | FEBS Open Bio |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7714078/ https://ncbi.nlm.nih.gov/pubmed/33098615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.13014 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|